Revenue segments as reported by the company.

BD Medical

BD Life Sciences

BD Interventional

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling and administrative

Research and development

Acquisition-related integration and restructuring

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Becton, Dickinson and Co.

Becton, Dickinson & Co. engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

BDX surpasses Q1 expectations, eyes growth amid market challenges

Becton, Dickinson and Co. delivered strong Q1 results, driven by the BD2025 strategy and successful product launches across segments.
While facing challenges in market dynamics and inflationary pressures, the company remains focused on margin expansion and operational efficiency.
Strategic investments, disciplined capital deployment, and a robust pipeline position BD for continued growth and performance improvement in FY 2023.

BDX reports strong Q2 performance, raises guidance for growth

Becton, Dickinson and Co. (BDX) demonstrated robust financial performance and strategic progress in Q2 2023, with raised guidance and a focus on long-term growth.
The company's strengths lie in innovation, efficiency, and sustainability initiatives, while facing challenges in operational execution and macroeconomic factors.
Opportunities for BDX include leveraging M&A for growth, capitalizing on healthcare transformation trends, and meeting long-term targets through sustained performance.
Overall, BDX's performance, strengths, challenges, and opportunities position it for continued success and resilience in the evolving healthcare landscape.

BDX reports robust Q3 earnings, focuses on Alaris system growth

BDX's Q3 earnings call highlighted strong financial performance, progress on BD2025 strategy, and strategic product launches.
The company aims to enhance operational efficiency, improve patient care, and drive revenue growth through innovative solutions.
Despite challenges like market backlog and macroeconomic factors, BD remains focused on long-term targets and margin expansion.

BD reports strong Q4 earnings, eyes growth amid challenges

BD's strong performance in Q4 and FY '23 driven by strategic initiatives and new product launches
Challenges in Q1 and macro environment expected to persist, but opportunities in new product launches and margin improvement
Focus on cash flow, margin improvement, and growth drivers to navigate challenges and drive value creation
Confidence in achieving operating margin guidance and strong performance in FY '24

Becton, Dickinson and Co. exceeds Q1 expectations, eyes growth opportunities

BD's Q1 performance was strong, with a focus on innovation and margin improvement initiatives driving robust cash flows.
Raised FY '24 guidance reflects confidence in revenue growth and margin expansion, despite potential challenges like FX moderation.
Opportunities for growth include market entry in molecular diagnostics and strategic capacity conversion in China.

BDX reports robust Q2 earnings, focuses on innovation and growth

Becton, Dickinson and Co. (BDX) delivered a strong Q2 performance, showcasing robust revenue, margin growth, and innovation. While facing challenges in market dynamics, BD remains focused on achieving its operating margin goal and capitalizing on opportunities for revenue acceleration and margin expansion.

BDX excels in Q3 with strong revenue growth and operational efficiency

Becton, Dickinson and Co. (BDX) showcased robust performance in Q3 2024, driven by organic revenue growth and operational excellence. While facing challenges in market dynamics, the company remains focused on innovation and growth strategies to achieve its financial targets and drive shareholder value.

BDX reports robust Q4 earnings, eyes growth amid market complexities

BDX delivered strong financial performance in Q4 2024, showcasing resilience and strategic focus amidst market challenges.
The company's emphasis on growth initiatives, operational excellence, and shareholder value underscores a commitment to sustainable growth.
While facing challenges such as market uncertainties and integration complexities, BD remains poised to leverage opportunities for growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Automatic Data Processing

CME Group

Ecolab

Gilead Sciences

Intercontinental Exchange

Merck

Public Service Enterprise Group

T. Rowe Price Group

Travelers

Walmart

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: December 12-20, 2021

Becton Dickinson & Co. Deposit Repr 1/20th Cum Conv Pfd Registered Series A

Becton Dickinson & Co. BDX, +0.90% said Monday that the spinoff of its diabetes care business will be named "embecta." The previously announced spinoff, into an independent publicly traded company, is expected to be completed in the second quarter of 2022.

Becton Dickinson to name diabetes care spinoff 'embecta'

FRANKLIN LAKES, N.J., Dec. 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that "embecta" [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold BD's Diabetes Care business upon the completion of the previously announced spinoff, which is expected to close in the second quarter of calendar year 2022.

BD Selects "embecta" as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team

Agilent Technologies

AmerisourceBergen

American Campus Communities

Ares Commercial Real Estate

American Equity Investment Life

Agnico Eagle Mines

Aflac

Assurant

Air Lease

American National Bankshares

Atmos Energy

Atlantica Sustainable Infrastructure

BOK Financial

Cadence Bank

Cabot

Cogent Communications Holdings

Cognex

City Hld

Community Healthcare Trust

CRA International

CTO Realty Growth

Coterra Energy

Monthly update of the Dividend Champions List. 75 companies declared higher dividends in the past month, with an average increase of 8.55% over their previous payouts.

Dividend Champions For December 2021

FRANKLIN LAKES, N.J., Dec. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI) — a disease that is the result of malfunctioning valves and can lead to varicose veins.

BD Acquires Venclose, Inc. To Extend Treatment Innovations In Chronic Venous Disease

FRANKLIN LAKES, N.J., Dec. 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the release of its 2021 Global Inclusion, Diversity and Equity (ID&E) Report.

BD Issues 2021 Global Inclusion, Diversity and Equity Report

FRANKLIN LAKES, N.J., Nov. 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern.

BD Statement on Testing for the COVID-19 Omicron Variant of Concern

Shares of Becton, Dickinson and Co. ( BDX , Financial) reported earnings results earlier this month that came in above Wall Street analysts' estimates. Covid-19 remains a tailwind to the company's business, but the core segments also performed well.

Becton, Dickinson & Co. Is Trading at a Discount

Amcor Plc

Cardinal Health

Caterpillar

Chubb

Clorox

General Dynamics

Hormel Foods

New Linde PLC

Lowe's

McDonald's

Medtronic

Nucor

Sysco

AT&T

V.F.

Walgreens

Even after the dip on Black Friday NOBL is still having a positive return in November. I present 3 strategies that theoretically can beat the dividend aristocrat index in the long term.

Best Dividend Aristocrats For December 2021

FRANKLIN LAKES, N.J., Nov. 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M.

BD Names Dr. Joseph M. Smith as Chief Scientific Officer

FRANKLIN LAKES, N.J., Nov. 24, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Francesca DeMartino has been named senior vice president of investor relations for the company, effective Nov. 29.

BD Names Francesca DeMartino as Senior Vice President of Investor Relations

Becton, Dickinson is one of the most stable predictable low-volatility health care stocks out there.

Becton, Dickinson Is A Strong Buy At $250

NIKE

Emerson Electric

Evergy Inc

Griffon

Huntington Ingalls Industries

Hawthorn Bancshares

Lancaster Colony

Matthews International

Mercury General

MDU Resources Group

McCormick

Motorola Solutions

Nelnet

Royal Gold

Roper Technologies

South Jersey Industries

Snap-on

Spire

York Water

Investors saw a few very good dividend increases in the first half of November, with ADP, Snap-on, and Roper Technologies announcing double-digit boosts, and a massive 29% boost from HP. The second half of November will bring double-digit boosts from a few more companies including Nike, Motorola Solutions, Aflac, and Agilent Technologies.

Second Half Of November Brings Dividend Increases From Merck, Nike And 12 Others

FRANKLIN LAKES, N.J., Nov. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will begin its Investor Day at 8 a.m.

BD to Highlight Progress Against BD 2025 Strategy and Plans for Long-Term Growth

News for Becton, Dickinson and Co. Stock (BDX)